Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGTC-501 in X-linked Retinitis Pigmentosa (RPGR)
2024-511181-36-00Phase 3Withdrawn
- Sponsor
- Beacon Therapeutics
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of laruparetigene zovaparvovec in X-linked retinitis pigmentosa (XLRP) (3 arms), sponsored by Beacon Therapeutics. Primary endpoint: Change from baseline in mean sensitivity across the whole grid by MAIA microperimetry at Month 12. Planned start Sep 2024; status: withdrawn.
02
Drugs
laruparetigene zovaparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on 2024-511181-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511181-36-00.